ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO002

Hemoperfusion With Seraph-100 Is Not Associated With Improved Survival in Severe COVID-19 Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Martinez, Maria, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Ardura, Paula, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Artola, Mercedes, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Lorenzo, Arturo, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Vasquez, Arinson, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Francisco, Amanda, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Acosta-Ochoa, Maria Isabel, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Bustamante, Maria, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Gonzalez, Pablo, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Bustamante, Elena, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
  • Coca, Armando, Hospital Clinico Universitario de Valladolid, Valladolid, Castilla y León, Spain
Background

Seraph-100 Blood Filter (ExThera Medical) is a hemoperfusion device designed to treat bloodstream infections. Its membrane binds pathogens, reducing bacterial and viral blood titers. The device received an authorization for emergency use in critically-ill COVID-19 patients by the FDA. We summarize the efficacy and safety profile of the device in a sample of COVID-19 ICU patients.

Methods

25 consecutive COVID-19 patients admitted in the ICU between Nov 2021 and Feb 2022 were retrospectively reviewed. 11 patients received a single treatment with Seraph-100 plus standard care. Subjects in the control group received standard care only.

Results

We found no differences between groups regarding age, sex or comorbidities. Treatment with Seraph was well tolerated and was associated with no modifications of leukocyte count or CRP levels. No differences regarding in-hospital mortality (LR=0.37;P=0.54) or length of ICU stay were observed. Patients treated with Seraph suffered Gram-positive associated pneumonia less frequently.

Conclusion

Seraph hemoperfusion was not associated with better results in our sample. This may be due to small sample size and high heterogeneity present in parameters such as disease severity, other complications, length of ICU stay or hemoperfusion dosage. To improve results it is necessary to better define the most appropriate timing and dosage for each case.